Spinal fluid drug shows promise for rare breast cancer complication

NCT ID NCT01373710

First seen Nov 25, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This study tested the drug trastuzumab, given directly into the spinal fluid, for people with HER2-positive breast cancer that spread to the lining of the brain (carcinomatous meningitis). The goal was to find a safe dose and see if it could slow the cancer's growth in the nervous system. 34 participants were enrolled. The approach aims to control the disease, not cure it, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Grenoble

    Grenoble, 38700, France

  • François Baclesse Center

    Caen, Calvados, 14076, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Curie - Claudius Regaud Hospital

    Paris, Île-de-France Region, 75248, France

  • Institut Univesitaire du Cancer de Toulouse

    Toulouse, 31100, France

  • Institut du Cancer de Montpellier

    Montpellier, 34298, France

  • Léon Bérard Center

    Lyon, Rhone, 69373, France

  • Oscar Lambret Center

    Lille, Nord, 59020, France

  • Pitie Salpetriere Hospital

    Paris, Île-de-France Region, 75651, France

  • Rene Huguenin Hospital

    Saint-Cloud, Haut de Seine, 92210, France

Conditions

Explore the condition pages connected to this study.